Neoadjuvant immune checkpoint inhibitor treatment + chemotherapy (vs. chemotherapy alone) for locally advanced non‑small cell lung cancer: A retrospective cohort study

Yang,Yi; Liu,Zaoyang

doi:10.3892/ol.2023.13878

Neoadjuvant immune checkpoint inhibitor treatment + chemotherapy (vs. chemotherapy alone) for locally advanced non‑small cell lung cancer: A retrospective cohort study

Authors:
- Yi Yang
- Zaoyang Liu
View Affiliations

Affiliations: Department of Thoracic Surgery, The Third People's Hospital of Chengdu, Chengdu, Sichuan 610082, P.R. China
Published online on: May 22, 2023 https://doi.org/10.3892/ol.2023.13878
Article Number: 292
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neoadjuvant immune checkpoint inhibitor (ICI) treatment + chemotherapy has been used for locally advanced non‑small cell lung cancer (NSCLC); however, evidence regarding the efficacy of this treatment is insufficient, particularly in Chinese patients. Therefore, the aim of the present study was to evaluate the efficacy and safety of neoadjuvant ICI treatment + chemotherapy compared with neoadjuvant chemotherapy alone for locally advanced NSCLC. For this, 50 patients with locally advanced NSCLC were retrospectively analyzed; of these, 23 patients received pre‑operative camrelizumab or sintilimab + chemotherapy (ICI + chemo group) and 27 patients received pre‑operative chemotherapy alone (chemo group). The objective response rate (73.9 vs. 44.4%, P=0.035) was superior in the ICI + chemo group compared with the chemo group. Nevertheless, surgical resection rate (100.0 vs. 88.9%, P=0.240), major pathological response (60.9 vs. 41.7%, P=0.188) and complete pathological response (CPR; 30.4 vs. 8.3%, P=0.072) were not significantly different in the ICI + chemo group compared with the chemo group. Following adjustment, ICI + chemo was independently associated with an elevated CPR (P=0.029). Disease‑free survival (DFS) was prolonged in the ICI + chemo group compared with the chemo group (1‑year DFS, 94.1 vs. 81.6%; 2‑year DFS, 80.7 vs. 42.9%; P=0.047), while no significant differences were observed in overall survival (OS; 1‑year OS, 100.0 vs. 95.7%; 2‑year OS, 90.0 vs. 64.9%; P=0.187). Additionally, the majority of adverse event incidences (apart from leukopenia) did not differ significantly between the ICI + chemo and chemo groups (all P>0.050). On the whole, the present study demonstrated that neoadjuvant ICI treatment + chemotherapy exhibited adequate efficacy and acceptable toxicity compared with chemotherapy alone in patients with locally advanced NSCLC.

View Figures

View References

1	Duma N, Santana-Davila R and Molina JR: Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
2	Mithoowani H and Febbraro M: Non-small-cell lung cancer in 2022: A review for general practitioners in oncology. Curr Oncol. 29:1828–1839. 2022. View Article : Google Scholar : PubMed/NCBI
3	Ricotti A, Sciannameo V, Balzi W, Roncadori A, Canavese P, Avitabile A, Massa I and Berchialla P: Incidence and prevalence analysis of non-small-cell and small-cell lung cancer using administrative data. Int J Environ Res Public Health. 18:90762021. View Article : Google Scholar : PubMed/NCBI
4	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
5	Alexander M, Kim SY and Cheng H: Update 2020: Management of non-small cell lung cancer. Lung. 198:897–907. 2020. View Article : Google Scholar : PubMed/NCBI
6	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, et al: NCCN guidelines insights: Non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 19:254–266. 2021. View Article : Google Scholar : PubMed/NCBI
7	Remon J, Soria JC and Peters S; ESMO Guidelines Committee. Electronic address, : simpleclinicalguidelines@esmo.org: Early and locally advanced non-small-cell lung cancer: An update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 32:1637–1642. 2021. View Article : Google Scholar : PubMed/NCBI
8	Puri S, Saltos A, Perez B, Le X and Gray JE: Locally advanced, unresectable non-small cell lung cancer. Curr Oncol Rep. 22:312020. View Article : Google Scholar : PubMed/NCBI
9	Ulas EB, Dickhoff C, Schneiders FL, Senan S and Bahce I: Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: A systematic review. ESMO Open. 6:1002442021. View Article : Google Scholar : PubMed/NCBI
10	Sławiński G, Wrona A, Dabrowska-Kugacka A, Raczak G and Lewicka E: Immune checkpoint inhibitors and cardiac toxicity in patients treated for non-small lung cancer: A review. Int J Mol Sci. 21:71952020. View Article : Google Scholar : PubMed/NCBI
11	Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, et al: Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 40:1301–1311. 2022. View Article : Google Scholar : PubMed/NCBI
12	Chen T, Ning J, Campisi A, Dell'Amore A, Ciarrocchi AP, Li Z, Song L, Huang J, Yang Y, Stella F and Luo Q: Neoadjuvant PD-1 inhibitors and chemotherapy for locally advanced NSCLC: A retrospective study. Ann Thorac Surg. 113:993–999. 2022. View Article : Google Scholar : PubMed/NCBI
13	Zhai H, Li W, Jiang K, Zhi Y and Yang Z: Neoadjuvant nivolumab and chemotherapy in patients with locally advanced non-small cell lung cancer: A retrospective study. Cancer Manag Res. 14:515–524. 2022. View Article : Google Scholar : PubMed/NCBI
14	Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, Tan DSW, Yang JC, Azrif M, Mitsudomi T, et al: Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 30:171–210. 2019. View Article : Google Scholar : PubMed/NCBI
15	Shamji FM and Beauchamp G: Assessment of operability and resectability in lung cancer. Thorac Surg Clin. 31:379–391. 2021. View Article : Google Scholar : PubMed/NCBI
16	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
17	Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, et al: Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial. Nat Med. 27:504–514. 2021. View Article : Google Scholar : PubMed/NCBI
18	Casarrubios M, Cruz-Bermúdez A, Nadal E, Insa A, García Campelo MDR, Lázaro M, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, et al: Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy. Clin Cancer Res. 27:5878–5890. 2021. View Article : Google Scholar : PubMed/NCBI
19	National Institutes of Health and National Cancer Institute, . Common terminology criteria for adverse events (CTCAE) version 4.0. Published:. May 28–2009.https://evs.nci.nih.gov/ftp1/CTCAE/About.html
20	Duan H, Wang T, Luo Z, Tong L, Dong X, Zhang Y, Afzal MZ, Correale P, Liu H, Jiang T and Yan X: Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: An open-label, multicenter, single-arm study. Transl Lung Cancer Res. 10:1020–1028. 2021. View Article : Google Scholar : PubMed/NCBI
21	Chen S, Zhao Z and Long H: Application of neoadjuvant immuno-chemotherapy in NSCLC. Zhongguo Fei Ai Za Zhi. 24:284–292. 2021.(In Chinese). PubMed/NCBI
22	Hou X, Shi X and Luo J: Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer. Oncol Lett. 24:2152022. View Article : Google Scholar : PubMed/NCBI
23	Zhang Y and Zhang Z: The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 17:807–821. 2020. View Article : Google Scholar : PubMed/NCBI
24	Emens LA and Middleton G: The interplay of immunotherapy and chemotherapy: Harnessing potential synergies. Cancer Immunol Res. 3:436–443. 2015. View Article : Google Scholar : PubMed/NCBI
25	Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, Rodriguez-Ruiz ME, Martínez-Forero I, Castañón E, López-Picazo JM, Sanmamed MF and Melero I: Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 11:1353–1367. 2021. View Article : Google Scholar : PubMed/NCBI
26	Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, et al: Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 21:1413–1422. 2020. View Article : Google Scholar : PubMed/NCBI
27	Mielgo-Rubio X, Uribelarrea EA, Cortés LQ and Moyano MS: Immunotherapy in non-small cell lung cancer: Update and new insights. J Clin Transl Res. 7:1–21. 2021.PubMed/NCBI
28	Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI
29	Hamada A, Soh J, Hata A, Nakamatsu K, Shimokawa M, Yatabe Y, Oizumi H, Tsuboi M, Horinouchi H, Yoshino I, et al: Phase II study of neoadjuvant concurrent chemo-immuno-radiation therapy followed by surgery and adjuvant immunotherapy for resectable stage IIIA-B (Discrete N2) non-small-cell lung cancer: SQUAT trial (WJOG 12119L). Clin Lung Cancer. 22:596–600. 2021. View Article : Google Scholar : PubMed/NCBI
30	Dickhoff C, Senan S, Schneiders FL, Veltman J, Hashemi S, Daniels JMA, Fransen M, Heineman DJ, Radonic T, van de Ven PM, et al: Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: The INCREASE trial. BMC Cancer. 20:7642020. View Article : Google Scholar : PubMed/NCBI
31	Zhao ZR, Yang CP, Chen S, Yu H, Lin YB, Lin YB, Qi H, Jin JT, Lian SS, Wang YZ, et al: Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. Oncoimmunology. 10:19960002021. View Article : Google Scholar : PubMed/NCBI
32	Aguado C, Chara L, Antoñanzas M, Matilla Gonzalez JM, Jiménez U, Hernanz R, Mielgo-Rubio X, Trujillo-Reyes JC and Couñago F: Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy. World J Clin Oncol. 13:314–322. 2022. View Article : Google Scholar : PubMed/NCBI